Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab.

Original post, click here

Ocrelizumab, OCREVUS

Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.